Limits...
A new curcuma extract (flexofytol®) in osteoarthritis: results from a belgian real-life experience.

Appelboom T, Maes N, Albert A - Open Rheumatol J (2014)

Bottom Line: Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life.Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months.We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

View Article: PubMed Central - PubMed

Affiliation: University of Brussels, Belgium.

ABSTRACT
This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

No MeSH data available.


Related in: MedlinePlus

Targets of the analgaesic effect of Flexofytol®.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4209497&req=5

Figure 2: Targets of the analgaesic effect of Flexofytol®.

Mentions: Although pain severity was more intense among patients with osteoarthritis of the knee (p=0.003), shoulder (p=0.016), or spine (p=0.0001), the analgesic effect of Flexofytol® was similarly reported in all these locations (Fig. 2). Patient perception of flexibility was less evident for the spine (p=0.023) but better for the hand (p=0.014), while clinical improvement over time was more evident for patients suffering from pain in the knee (p=0.0045) or in the hip (p=0.036; Fig. 3). Quality of life improved overt time, but less among patients suffering from low back pain (p=0.0004) or hip pain (p=0.012). This study also revealed that higher pain scores were associated with higher numbers of painful osteoarthritic lesions. More lesions were also associated with lower general evaluations of articular flexibility and quality of life. (p=0.041) (similar benefits of Flexofytol® were reported whether the patient suffered from one or more painful joints).


A new curcuma extract (flexofytol®) in osteoarthritis: results from a belgian real-life experience.

Appelboom T, Maes N, Albert A - Open Rheumatol J (2014)

Targets of the analgaesic effect of Flexofytol®.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4209497&req=5

Figure 2: Targets of the analgaesic effect of Flexofytol®.
Mentions: Although pain severity was more intense among patients with osteoarthritis of the knee (p=0.003), shoulder (p=0.016), or spine (p=0.0001), the analgesic effect of Flexofytol® was similarly reported in all these locations (Fig. 2). Patient perception of flexibility was less evident for the spine (p=0.023) but better for the hand (p=0.014), while clinical improvement over time was more evident for patients suffering from pain in the knee (p=0.0045) or in the hip (p=0.036; Fig. 3). Quality of life improved overt time, but less among patients suffering from low back pain (p=0.0004) or hip pain (p=0.012). This study also revealed that higher pain scores were associated with higher numbers of painful osteoarthritic lesions. More lesions were also associated with lower general evaluations of articular flexibility and quality of life. (p=0.041) (similar benefits of Flexofytol® were reported whether the patient suffered from one or more painful joints).

Bottom Line: Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life.Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months.We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

View Article: PubMed Central - PubMed

Affiliation: University of Brussels, Belgium.

ABSTRACT
This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

No MeSH data available.


Related in: MedlinePlus